The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
01-Dec-10
$100 million
Target:
Clyde Process Solutions plc
Acquiror:
S-Process Equipment International S.à r.l. (Schenck Process)
Advised S-Process Equipment International S.à r.l. (“Schenck Process”), a global leader in bulk material handling, providing applications incorporating weighing, feeding, screening and automation solutions, on its acquisition of Clyde Process Solutions plc, a global provider of pneumatic conveying and air filtration solutions for process industries
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
16-Sep-10
$NA
Target:
KemFine UK Ltd
Acquiror:
AURELIUS AG
Advised KemFine Group Oy, a 3i portfolio company, on the sale of its UK-based fine chemicals business, KemFine UK Ltd, to AURELIUS AG
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
12-Oct-08
$6.0 billion
Target:
Hapag-Lloyd AG
Acquiror:
Albert Ballin KG
Advised TUI AG, Europe’s largest tourism company, on its sale of its shipping division Hapag-Lloyd AG, one of the leading global container shipping companies
08-Oct-08
$NA
Target:
MAN Ferrostaal AG
Acquiror:
International Petroleum Investment Company (IPIC)
Advised MAN AG in relation to its 70% sale of MAN Ferrostaal AG, a worldwide supplier of industrial services for the construction of large-scale industrial plants and machine supply, to International Petroleum Investment Company (IPIC)
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
31-Jul-07
$491 million
Target:
DEUTZ Power Systems
Acquiror:
3i
Sole advisor to DEUTZ AG on the divestiture of its division DEUTZ Power Systems, a leading manufacturer of gas fired engines for decentralized power generation
25-Jun-07
$8.1 billion
Target:
Energy East Corporation
Acquiror:
Iberdrola SA
Advised Energy East Corporation, a super-regional electric and gas utility with nearly 3 million regulated customers in the northeast US, on its sale to Iberdrola SA
18-Dec-06
$NA
Target:
InBev SA
Acquiror:
Mr. Wolfgang Dinkelacker
Advised InBev SA, the world's largest brewery, on the sale of German regional brewery Dinkelacker-Schwaben Bräu KG
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
20-Feb-06
$254 million
Target:
Textile Effects
Acquiror:
Huntsman Corporation
(division of Ciba Specialty Chemicals AG)
Advised Ciba Specialty Chemicals AG on the sale of its global Textile Effects business
28-Nov-05
$103 million
Target:
Akzo Nobel N.V.
Acquiror:
Hexion Specialty Chemicals Inc.
(Ink and Adhesive Resins business) Advised Akzo Nobel N.V., a global leader in coatings, chemicals and healthcare on the sale of its Ink and Adhesive Resins business to Hexion Specialty Chemicals Inc
20-Oct-05
$NA
Target:
Drakkar Holdings SA (Adisseo Group)
Acquiror:
China National Chemical Corporation
Advised CVC Capital Partners on the divestiture of Adisseo via the sale of Drakkar Holdings SA to China National BlueStar, a subsidiary of state-owned diversified chemicals company China National Chemical Corporation. Adisseo is a leading player in the animal nutrition market